{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:27:45Z","timestamp":1790782065663,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1136\/ijgc-2022-004142","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T09:12:26Z","timestamp":1678266746000},"page":"1044-1050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort"],"prefix":"10.1016","volume":"33","author":[{"given":"Hannah","family":"Karpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Manderski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-2061","authenticated-orcid":false,"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004142_bb0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.6004\/jnccn.2016.0123","article-title":"Next-generation sequencing: role in gynecologic cancers","volume":"14","author":"Evans","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2022-004142_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ajcp\/aqaa256","article-title":"The utility of next-generation sequencing in advanced breast and gynecologic cancers","volume":"156","author":"Jones","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1136\/ijgc-2022-004142_bb0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JOP.19.00201","article-title":"When should tumor genomic profiling prompt consideration of germline testing?","volume":"15","author":"DeLeonardis","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2022-004142_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0030","unstructured":"J Stewart . Keytruda FDA approval history. Available: https:\/\/www.drugs.com\/history\/keytruda.html [Accessed 13 Aug 2022]."},{"key":"10.1136\/ijgc-2022-004142_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020308","article-title":"Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification","volume":"18","author":"Kamps","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ijgc-2022-004142_bb0040","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41436-020-0783-8","article-title":"Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"Li","year":"2020","journal-title":"Genet Med"},{"key":"10.1136\/ijgc-2022-004142_bb0045","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ijc.29128","article-title":"Tumor genome analysis includes germline genome: are we ready for surprises?","volume":"136","author":"Catenacci","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-004142_bb0050","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/annonc\/mdw018","article-title":"Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol","volume":"27","author":"Meric-Bernstam","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA [published correction appears in JAMA oncol. 2016 feb;2(2):279. hyman, david [corrected to hyman, david M]]","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0065","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1158\/1078-0432.CCR-16-0015","article-title":"Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings","volume":"22","author":"Seifert","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004142_bb0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10689-015-9817-9","article-title":"Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines","volume":"14","author":"Marcus","year":"2015","journal-title":"Fam Cancer"},{"key":"10.1136\/ijgc-2022-004142_bb0075","article-title":"NCCN clincal practice guidelines in oncology: ovarian neoplasms","volume":"1","year":"2021","journal-title":"Version"},{"key":"10.1136\/ijgc-2022-004142_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-018-0383-5","article-title":"Additional germline findings from a tumor profiling program","volume":"11","author":"Stjepanovic","year":"2018","journal-title":"BMC Med Genomics"},{"key":"10.1136\/ijgc-2022-004142_bb0085","first-page":"00182","article-title":"Decision-making preferences about secondary germline findings that arise from tumor genomic profiling among patients with advanced cancers","volume":"1","author":"Hamilton","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0090","first-page":"31","article-title":"Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy","volume":"70","author":"Alcaraz","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-004142_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42703","article-title":"Use of germline BRCA testing in patients with ovarian cancer and commercial insurance","volume":"5","author":"Cham","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2022-004142_bb0100","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.cgh.2018.08.038","article-title":"Low referral rate for genetic testing in racially and ethnically diverse patients despite universal colorectal cancer screening","volume":"16","author":"Muller","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/ijgc-2022-004142_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2017.10.034","article-title":"Disparities in genetics assessment for women with ovarian cancer: can we do better?","volume":"149","author":"Manrriquez","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0110","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2015.66.3658","article-title":"The effects of oncologist implicit racial bias in racially discordant oncology interactions","volume":"34","author":"Penner","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0115","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.2105\/AJPH.2015.302903","article-title":"Implicit racial\/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review","volume":"105","author":"Hall","year":"2015","journal-title":"Am J Public Health"},{"key":"10.1136\/ijgc-2022-004142_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19052598","article-title":"The role of medical mistrust in concerns about tumor genomic profiling among black and African American cancer patients","volume":"19","author":"Hoadley","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1136\/ijgc-2022-004142_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajmg.c.31604","article-title":"Genetic counseling among minority populations in the era of precision medicine","volume":"178","author":"Halbert","year":"2018","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1136\/ijgc-2022-004142_bb0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","article-title":"Disparities in germline testing among racial minorities with prostate cancer","volume":"25","author":"Weise","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1136\/ijgc-2022-004142_bb0135","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","article-title":"Racial differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer","volume":"293","author":"Armstrong","year":"2005","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-004142_bb0140","first-page":"00076","article-title":"Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing","volume":"3","author":"Clark","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38167","article-title":"Comparison of germline genetic testing before and after a medical policy covering universal testing among patients with colorectal cancer","volume":"5","author":"Moretz","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2022-004142_bb0150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","article-title":"Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","volume":"29","author":"Ring","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2022-004142_bb0155","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/PO.21.00249","article-title":"Up-front multigene panel testing for cancer susceptibility in patients with newly diagnosed endometrial cancer: a multicenter prospective study","volume":"5","author":"Levine","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0160","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2022.04.003","article-title":"Utility of germline multi-gene panel testing in patients with endometrial cancer","volume":"165","author":"Karpel","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0165","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/jmedgenet-2021-108062","article-title":"Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives","volume":"59","author":"Salikhanov","year":"2022","journal-title":"J Med Genet"},{"key":"10.1136\/ijgc-2022-004142_bb0170","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.gim.2022.01.017","article-title":"Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States","volume":"24","author":"Guzauskas","year":"2022","journal-title":"Genet Med"},{"key":"10.1136\/ijgc-2022-004142_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2018.07.023","article-title":"Missed opportunities: genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer","volume":"151","author":"Lee","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004142_bb0180","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.19.00160","article-title":"The time for mainstreaming germline testing for patients with breast cancer is now","volume":"37","author":"Rajagopal","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:40:15Z","timestamp":1753101615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24016116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1048891X24016116"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004142","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}